Bank of Stockton Purchases 610 Shares of Illumina, Inc. (NASDAQ:ILMN)

Bank of Stockton boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 28.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,772 shares of the life sciences company’s stock after acquiring an additional 610 shares during the period. Bank of Stockton’s holdings in Illumina were worth $220,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Rakuten Securities Inc. increased its stake in shares of Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 270 shares during the period. Center for Financial Planning Inc. acquired a new position in Illumina during the 1st quarter valued at $33,000. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the fourth quarter valued at about $40,000. PFS Partners LLC grew its position in Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after buying an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC increased its stake in Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 292 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ILMN shares. Citigroup lowered their price objective on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. JPMorgan Chase & Co. reduced their price objective on shares of Illumina from $120.00 to $85.00 and set a “neutral” rating for the company in a report on Friday, May 9th. Robert W. Baird decreased their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Stephens reissued an “overweight” rating and issued a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Finally, Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and a consensus price target of $127.39.

Insiders Place Their Bets

In other Illumina news, CFO Ankur Dhingra purchased 6,100 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares in the company, valued at approximately $2,022,616.26. This represents a 32.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.60% of the company’s stock.

Illumina Price Performance

ILMN opened at $93.23 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48. The stock has a market capitalization of $14.76 billion, a P/E ratio of -15.36, a price-to-earnings-growth ratio of 1.80 and a beta of 1.32. The company’s 50 day simple moving average is $81.76 and its 200-day simple moving average is $100.05. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same period last year, the company earned $0.98 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.